Litcius/Paper detail

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca, Olivier Tournilhac, Wojciech Jurczak, Anna Marina Liberati, Zsolt Nagy, Aleš Obr, Gianluca Gaïdano, Marc André, Nagesh Kalakonda, Martin Dreyling, Johannes Weirather, Maren Dirnberger‐Hertweck, Sumeet Ambarkhane, Günter Fingerle‐Rowson, Kami J. Maddocks

2020The Lancet Oncology519 citationsDOIOpen Access PDF

Topics & Concepts

LenalidomideDiffuse large B-cell lymphomaRefractory (planetary science)MedicineLymphomaOncologyInternal medicineMultiple myelomaMaterials scienceComposite materialMonoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and TreatmentHER2/EGFR in Cancer Research